Drugs / Caralluma Fimbriata
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05232266 | Feb 2022 → May 2023 | — | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caralluma Fimbriata | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05232266 ↗ |